ReEmerge Raises $37M to Advance Brain Injury Technology
Boston, Massachusetts, U.S., September 15, 2026 ReEmerge, Inc. has emerged from stealth with an oversubscribed $37 million Series A...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Boston, Massachusetts, U.S., September 15, 2026 ReEmerge, Inc. has emerged from stealth with an oversubscribed $37 million Series A...
ROME & CORAL GABLES, Fla., July 16, 2026 Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, marking a...
LONDON, UK, July 6, 2026 Cumulus Neuroscience announced a strategic collaboration with Muse by Interaxon to integrate validated at-home...
INDIANAPOLIS, June 24, 2026 Eli Lilly and Company announced the successful completion of its acquisition of Centessa Pharmaceuticals plc,...
BOSTON, Mass., June 20, 2026 Velico Medical has announced successful results from its Phase 1 first-in-human clinical trial evaluating...
MISSION VIEJO, Calif., June 20, 2026 Kyowa Hakko USA has unveiled promising new research demonstrating the potential acute cognitive...
HOUSTON, Texas, June 16, 2026 Nexalin Technology announced that two clinical abstracts evaluating its proprietary Deep Intracranial Frequency Stimulation...
GOTHENBURG, Sweden, June 13, 2026 MGI Tech Co., Ltd. (MGI) unveiled major initiatives to strengthen the global genomics ecosystem...
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
JACKSONVILLE, Fla., June 11, 2026 Johnson & Johnson has announced the expanded U.S. availability of its TECNIS PureSee Intraocular...
